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 Abstract 
 Sonodynamic therapy (SDT) is a newly developed anticancer 
treatment where ultrasound is used to trigger the cytotoxic 
effect of chemical compounds, known as sonosensitizers. 
Although SDT is similar to photodynamic therapy (PDT), 
SDT activates the chemical compounds through energy 
transfer using ultrasound rather than light. Moreover, SDT 
can focus the ultrasound energy onto malignant sites situa-
ted deeply within tissues, thus overcoming the main draw-
back linked to the use of PDT. Several physical and chemical 
mechanisms underlying ultrasound bioeffects and anticancer 
SDT take advantage of the non-thermal effect of acoustic 
cavitation generated by selected pulsed or continuous ultra-
sound. As the physical-chemical structure of the sonosentizer 
is essential for the success of SDT, we believe that the dif-
ferent aspects related to nanotechnology in medicine might 
well be able to improve the triggering effect ultrasound has on 
sonosensitizing agents. Therefore, the aim of this review is to 
focus on how nanotechnology might improve this innovative 
anticancer therapeutic approach. 
 Keywords:  cancer;  nanoparticles;  sonodynamic therapy; 
 sonosensitizers;  ultrasound. 
 1. Introduction 
 Ultrasonic waves are commonly described as waves that 
transport mechanical energy through the local vibration of 
particles without any net transport of the particles them-
selves. The term  “ ultrasound ” is generally taken to mean 
that the frequency of the wave is greater than the upper 
threshold limit human hearing can detect. Therefore, ultra-
sound is a mechanical wave with periodic vibrations of 
particles in a continuous, elastic medium at frequencies 
≥20 kHz  [1] . 
 Nowadays, ultrasound is commonly used in most biomedi-
cal applications, both in the fi eld of diagnosis and therapy, 
requiring better localization/focusing and higher frequencies 
(Table  1 ). However, even if ultrasound is generally considered 
 “ safe, ” as no harmful effects have been associated with their 
medical use, it can affect tissue through a variety of mecha-
nisms, mainly thermal or non-thermal, depending on various 
factors such as the intensity of the beam and the duration of 
exposure and frequency (American Institute of Ultrasound in 
Medicine)  [1] . 
 There are several underlying mechanisms in ultrasound, 
i.e., streaming and radiation forces, but the most prominent 
mechanical effect on tissue is acoustic cavitation, which is 
defi ned as the formation or activity of gas- or vapor-fi lled 
cavities (bubbles) in a medium exposed to an ultrasound 
fi eld  [2] . 
 Nanotechnology is defi ned as the study and use of struc-
tures with a size that varies between 1 and 100 nm. The last 
few decades have witnessed an increase in the ability to 
manage nanosized materials, consequently, a world of pos-
sibilities in a variety of industries and scientifi c endeavors 
has been opened. As nanotechnology is essentially a set of 
techniques that allow for the manipulation of properties on a 
very small scale, it may have many and far-reaching applica-
tions. Indeed, one such important area is that of  “ nanomedi-
cine, ” which, according to the National Institute of Health 
Nanomedicine Roadmap Initiative, refers to highly specifi c 
medical interventions at a molecular level for the diagno-
sis, prevention, and treatment of diseases  [3] . Drug-delivery 
nanosystems make for a signifi cant portion of nanomedicine. 
The importance of nanotechnology in drug delivery is in the 
concept and ability to manipulate molecules and supramo-
lecular structures to produce devices with programmed func-
tions. Clinically useful drug-delivery systems must be able to 
deliver a therapeutically effective amount of a drug, which is, 
more often than not, to be done over an extended period. The 
interaction of drug carrier systems with the biological envi-
ronment is an important element on which to base and design 
strategies. These systems should be independent in the envi-
ronment and selective at the pharmacological site. If appro-
priately designed, nanoparticles not only may act as a drug 
vehicle capable of targeting tumor tissues and/or cells but 
also offer a protective barrier against drug inactivation during 
transport. Therefore, the purpose of this review is to focus on 
how nanotechnology and, in particular, nanoparticles might 
improve the sonodynamic therapy (SDT) of cancer. 
 2. Acoustic cavitation 
 The non-thermal interaction of ultrasound with bulk liquid 
is accompanied by the quite unique phenomenon of cavita-
tion, which leads to an enormous concentration and conver-
sion of the diffused sound energy. Cavitation has at least 
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 Table 1  Frequency ranges and associated applications. 
16 Hz–20 kHz Human hearing
20–100 kHz Conventional power ultrasound
20 kHz–3 MHz Sonochemistry
1–3 MHz Physiotherapy
3–30 MHz Diagnostic ultrasound
three discrete stages: nucleation, bubble growth and, under 
proper conditions, implosive collapse. The dynamics of 
cavity growth and collapse are strikingly dependent on the 
local environment; cavity collapse in a homogeneous liq-
uid differs greatly from cavitation near an extended liquid 
solid interface  [4, 5] . Cavitation has been classifi ed into two 
types: non-inertial and inertial. Non-inertial cavitation bub-
bles oscillate about an equilibrium radius and often persist 
for many acoustic cycles. These oscillations create a stream-
ing of surrounding liquid and mechanical stresses mix the 
medium. Inertial cavities are gas bubbles that grow to near-
resonance size and may expand to a maximum, before col-
lapsing violently (Figure  1 ). The temperature and pressure 
on the material contained within the imploding cavities can 
reach values >10,000 K and 800 atm. These extreme condi-
tions may induce a multitude of chemical reactions (sono-
chemistry) both within and surrounding the bubble, including 
a concentration of energy that can generate light, an emission 
known as sonoluminescence  [6] . 
 Therefore, the wide range of application of acoustic cavita-
tion also includes the direct interaction between the ultrasound 
and the biological membrane, modifying their permeability 
 [7] . Indeed, ultrasound seems to be capable of modifying 
drug distribution in the human body, and it is hoped that a 
better understanding of such mechanisms will result in the 
optimization of drug therapies. Recently, numerous reports 
have been published on the application of ultrasound energy 
to target and/or control drug release in the fi elds of throm-
bolytic agents, transdermal drug delivery, anticancer drugs, 
and gene therapy  [8] . Therefore, applying acoustic cavitation 
in an effort to increase the drug bioavailability is a very pro-
mising approach to drug-delivery systems and can be applied 
in different ways. First, ultrasound energy has the capacity to 
help agents penetrate through various tissues. Acoustic force 
is able to drive materials deeply into the skin, blood clots, or 
 Figure 1  Drawing showing the formation, growth, and collapse of 
a cavitation bubble. 
other tissue. Researchers have hypothesized that these micro-
jets, or the so-called microstreaming, could be applied to pro-
mote the diffusion of drugs into various tissues and lesions 
 [7 – 9] . Indeed, acoustic energy exposure to specifi c cells by 
ultrasound, or shock waves, produced by lithotripters, have 
demonstrated an enhanced uptake of drugs within cells  [8] . 
Another aspect is the use of the microbubbles to carry various 
drugs to target sites then rupturing the microbubbles by local-
ized ultrasound energy. Indeed, albumin microbubbles were 
fi rst used to further enhance the effects of thrombolytic agents 
when used in conjunction with ultrasound  [10] . At moderately 
high sound pressure, amplitudes at the acoustic pressure waves 
can cause the rupturing of coated microbubble shells, allow-
ing the bubbles to behave as non-coated microbubbles until 
they diffuse into the bloodstream. Moreover, drug-fi lled or 
drug-coated microspheres containing a therapeutic compound 
may be targeted to specifi c tissues through sonic energy that 
is directed to the target area and ruptures the microspheres, 
releasing the therapeutic compound. Even if the exact mecha-
nism is still unknown, it is likely that the most exciting appli-
cation of this method could well be gene therapy  [11] . It is 
believed that once microspheres are ruptured, they can create 
a local increase in membrane fl uidity, thereby enhancing the 
cellular uptake of the therapeutic compound  [8] . Furthermore, 
targeted drug delivery assumes particular importance where 
drug toxicity is to be taken into careful consideration. 
 Ultrasound not only can enhance the drug bioavailability  in 
vitro and  in vivo , but they can also change the chemical prop-
erty of the drug itself. It has been reported that light-sensitive 
materials, such as non-toxic agents such as hematoporphy-
rins, can be activated by ultrasound and may kill cancer cells 
 [12] . Researchers discovered that non-thermal ultrasound 
may activate a group of chemicals that were originally used as 
light-activated chemicals for cancer therapy through acoustic 
cavitation, and this innovative ultrasound therapy has been 
termed  “ sonodynamic therapy ”  [8] . 
 3. Sonodynamic therapy 
 SDT is one of the non-invasive therapeutic applications of 
ultrasound that has been considered in the last few decades 
 [8, 13 – 15] . Although SDT is currently under investigation 
by researchers across the globe, this therapeutic approach is 
still in its early stage. Cytotoxicity is induced in SDT after 
the accumulation of a sonosensitizing agent in tumor cells by 
ultrasonic exposure through the activation of the sonosensi-
tizer. As dedicated acoustic lenses can focus ultrasound into 
a limited focal zone, they are able to penetrate into the non-
superfi cial tissues. The extent of the focal zone and penetra-
tion depth of ultrasound depend on both the focusing grade of 
the lens and the wave frequency  [16] . 
 Heat and mechanical effects are the most common bioef-
fects associated with ultrasound exposure and are both inten-
sity and frequency dependent  [14] . Therefore, the acoustic 
parameters for ultrasound therapy must be selected with care, 
taking the objective into consideration. The ultrasonic  “ level ” 
may be determined by intensity, and Yu et al.  [14] suggested 
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2 W/cm 2 as the critical value between low- and high-level 
ultrasound. Thus, ultrasound waves, which mostly induce 
structural alterations, have a high-level intensity, whereas 
those that mainly modulate tissue functions have a low 
level  [14] . The thermal applications of ultrasound, such as 
high-intensity focused ultrasound (HIFU)  [17] , have been 
more extensively studied than has the therapeutic use of the 
non-thermal effects of ultrasound, even though it has been 
reported that free radical scavengers and antioxidants, such as 
mannitol, vitamins C and E, and superoxide dismutase, could 
reduce cavitation-induced tissue damage  [18] . 
 One way to minimize heating is by using pulsed (e.g., shock 
waves), rather than continuous ultrasound  [19, 20] . Generally, 
a high-energy shock wave (HESW) can be described as a 
single pulse with a wide frequency range (up to 20 MHz), high-
pressure amplitude (up to 120 MPa), low tensile wave (up to 
10 MPa), small pulse width at -6 dB, and a short rise time 
( < 10 ns) (Figure  2 ). The energy density (up to 1.5 mJ/mm 2 ) 
and the pulse energy (up to 100 mJ) determine the tempo-
ral and spatial distribution of the pressure profi le. The energy 
density describes the maximum amount of acoustical energy, 
which is transmitted through an area of 1 mm 2 per pulse  [15] . 
Mechanical stresses seem to play a major role in high-energy 
shock waves, where the acoustic pressure, frequency of the 
applied ultrasound, pulse duration, and most importantly, 
the extent of nucleation of the exposed medium infl uence the 
occurrence of inertial cavitation. The likelihood of nucleation 
increases as the ultrasonic pressure amplitude increases. 
 As the sonosensitizers used in SDT have no or very low 
cytotoxicity without ultrasound stimulation, the cytotoxic 
effects of SDT only occur in the area where the localized 
ultrasound is applied (Figure  3 ). SDT, whether pulsed or con-
tinuous ultrasound, is considered to be safer and more readily 
accepted by the patient than either radiotherapy or chemo-
therapy, which often give rise to source concerns of safety 
and side effects  [8] . SDT differs from photodynamic therapy 
(PDT), as drug activation is achieved through ultrasound 
rather than light. Moreover, SDT is able to overcome the main 
drawback of PDT, i.e., the relatively limited penetration of 
 Figure 2  Pressure waveform of a shock wave as a function of 
time. 
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 Figure 3  Anticancer SDT: cytotoxicity in tumor tissue when a 
sonosensitizer as been activated by focused ultrasound (hematoxy-
lin and eosin staining of DHD/K12/TRb tumors photographed under 
light microscope at a 10 × magnifi cation  [20] ). 
 Table 2  Porphyrin-related sonosensitizers. 
Sonosensitizers Ref. Sonosensitizers Ref.
ATX-70  [21] Photoprin II  [22] 
ATX-S10  [22] Phthalocyanine  [25] 
Chlorin-e6  [23] Protoporphirin IX  [24] 
DCPH-P-Na  [22] SF1 and SF2  [26] 
Hematoporphyrin  [24] SL052  [27] 
light into human tissue, and even at the longer wavelengths, 
light can penetrate no more than 5 mm into tissue. This goes 
without saying that this limits such treatments to surface (top-
ical) applications, limiting PDT ’ s application on superfi cial 
tumors, those that are directly underneath the skin surface, or 
on the surface of internal organs. Furthermore, in SDT, ultra-
sound may be used as an external remote control over time, 
dose, and location of drug release, providing tailor-made and 
localized cancer therapy  [13] . 
 A series of  in vitro and  in vivo trials confi rmed that SDT, 
where either ultrasound or sonosensitizer had no or very low 
cytotoxicity, was effi cacious in destroying malignant cells/tis-
sues, and most sonosensitizers are either porphyrins or their 
derivatives (Table  2 )  [16, 21 – 27] . 
 Protoporphyrin IX (PPIX) is an effi cient hydrophobic 
tumor-localizing agent  [28] that can be activated by both 
light and ultrasound  [29] . The subsequent interaction of 
activated PPIX with molecular oxygen produces a cytotoxic 
reactive oxygen species (ROS), particularly singlet oxygen, 
which leads to an irreversible destruction of the target tis-
sue. As the activation of the sonosensitizer is dependent on 
the cavitation process; high intensity ultrasound is a must. 
This followed the assumption that ultrasound energy might 
cause electronic excitation of porphyrins by energy transfer 
and initiate a photochemical process resulting in the forma-
tion of the cytotoxic singlet oxygen (Figure  4 ). Moreover, as 
opposed to anticancer drugs, porphyrins are non-toxic in the 
absence of ultrasound. 
 Unfortunately, some sonosensitizers have physical-chemical 
proprieties that seriously limit their clinical applications, such 
as poor water solubility. This is mainly true of natural prod-
ucts, such as hypocrellin, and nanotechnology is one method 
that can be adopted to solve such problems  [27] . 
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 Generally, nanoformulation plays an important role in 
improving drug delivery by making the drug more water-
soluble without changing its physical-chemical structure. 
Furthermore, nanomodifi cation allows the drug to be deliv-
ered to some deeply seated malignant sites that are not easily 
accessible to drugs. Therefore, we believe that nanotechnol-
ogy approaches will improve SDT considerably. 
 4. Nanoparticles as a sonosensitizer delivery 
system 
 The tissue distribution of sonosensitizers is agent dependent 
and thus gives rise to several drawbacks in the bioavailability 
of sonosensitizing agents, as the therapeutic concentration of 
the chemical in a specifi c tissue may not be reached. That is to 
say, the concentration gradient between the malignant tissue 
and its adjacent normal tissue may not be suffi ciently high to 
safely carry out SDT and the concentration in the target tis-
sue might be lower than that in plasma, resulting in hemoly-
sis and blood cell rupture. Therefore, the clinical application 
of today ’ s sensitizers is not free from problems. Indeed, as 
most sonosensitizer molecules are hydrophobic and are con-
sequently easily aggregated in aqueous media, the sonosen-
sitizer aggregation decreases its effi cacy for singlet oxygen 
production. Moreover, the aggregated sonosensitizer cannot 
be simply injected intravenously. 
 Yang et al.  [30] describe an oral form of nanoparticles that 
encapsulate 5-aminolevulinic acid (5-ALA), a precursor of 
the sonosensitizer PPIX. Chitosan was mixed with sodium 
tripolyphosphate, and 5-ALA loaded chitosan nanoparticles 
(CNA) through the addition of 5-ALA with different pH 
Transcription
(NF-κB, AP-1,
Nrf2, p53)
Signal
transductionCell survival
or death (MAPK,
PI3K/Akt, p53)
Execution
(Caspases, BCL-2,
cyt C, p53)
Cell death
ROS production
(O2
- HO• H2O2)
 Figure 4  Redox-sensitive proteins that can regulate the cell fate 
decision through the regulation of signal transduction, transcriptional 
regulation, or execution. Not only does oxidative stress serve as a 
type of stimulus to trigger stress-response signal transduction path-
ways, but it can also modulate cell death/survival through direct oxi-
dative modifi cation of those signal molecules. ROS include radical 
species, such as superoxide (O 2 - ) and hydroxyl radical (HO  •  ) along 
with nonradical species, such as hydrogen peroxide (H 2 O 2 ). 
values and concentrations. The results revealed that particle 
size with different  ζ -potential could be manipulated by the 
addition of 5-ALA with different concentrations and pH val-
ues. CNA particles, prepared at pH 7.4 and pH 9 of 5-ALA 
solutions at a concentration >0.5 mg/ml, showed a promising 
loading effi ciency of up to 75 % and an optimum average par-
ticle size of 100 nm. 
 The triblock copolymer, Pluronic P105 (BASF, Mount 
Olive, NJ, USA), has been found to be an ideal ultrasonically 
activated drug-delivery vehicle  [31] . The copolymer forms 
dense micelles with strongly hydrophobic cores at concentra-
tions of 4 wt % or above and the polypropylene oxide core 
is suffi ciently hydrophobic to sequester hydrophobic com-
pounds. These micelles have been shown to release their 
contents upon the application of low-frequency ultrasound, 
suggesting that drug molecules can be delivered specifi cally 
to the insonated regions. Furthermore, once the ultrasound 
is turned off, the drug is quickly re-encapsulated inside the 
core of the micelles, preventing the spread of drug outside 
the targeted region  [31] . The circulation time of the encapsu-
lated drug is increased by polyethylene glycol (PEG) chains 
and prevents the carrier from being cleared by cells in the 
reticuloendothelial system. Indeed, pluronic micelles are 
large enough to escape renal excretion but small enough to 
extravasate at the tumor site. As pluronic has been shown to 
be non-toxic at low concentrations, it has been used to over-
come multidrug resistance. Husseini et al.  [32, 33] used an 
ultrasonic exposure chamber with real-time fl uorescence 
detection to measure the release of doxorubicin from unstabi-
lized and stabilized Pluronic P105 micelles through ultrasonic 
stimulation. Ultrasonic intensity increases the amount of drug 
release and frequency decreases it. Such ultrasonically con-
trolled release has been effective against cancer cells both  in 
vitro and  in vivo  [31, 34] . It is noteworthy that the amount 
of release is not a linear function of ultrasonic intensity. In 
particular, there is a threshold at 0.3 W/cm 2 . Observations 
of thresholds associated with cavitation and other ultrasonic 
phenomena are not unusual, and the existence of a thresh-
old for the onset of inertial or collapse cavitation has been 
extensively documented  [35, 36] . Other authors  [1, 37] have 
calculated the threshold for the onset of inertial cavitation as 
a function of frequency and bubble size. Ultrasonic intensity 
thresholds reported for an observed biological effect  [1, 11, 
35, 38] usually differ from thresholds for collapse cavitation 
and vary according to the type of cell or tissue and the mecha-
nism producing the effect (cell permeability, DNA delivery, 
cell lysis, or tissue damage)  [31] . Husseini et al.  [31] sug-
gest that the increase in background acoustic emission, due 
to the wide spectrum of frequencies of shock waves (white 
noise), establishes the connection among collapse cavitation, 
the appearance of the subharmonic, and drug release from the 
micelles. Therefore, collapse cavitation may be involved in 
drug release, most probably through high shear forces that 
disrupt the structure of the micelle. 
 Drug delivery through nanoparticles is not the only 
approach that can enhance SDT (Figure  5 ). Indeed, the exis-
tence of a particle in a liquid provides a nucleation site for 
the cavitation bubble and, due to its surface roughness, leads 
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 Figure 5  Nanoparticles for sonosensitizing activity as sonosensi-
tizer drug-delivery system and as nanosonosensitizers and for selec-
tive targeting as antibody-targeted and PEG-grafted nanoparticles. 
to a decrease in the cavitation threshold responsible for the 
increase in the quantity of bubbles when the liquid is irra-
diated by ultrasound. Therefore, in this context, another 
nanotechnology approach might be based on providing the 
nucleation sites that participate in the formation of cavities to 
reduce the threshold intensity required for cavitation  [39] . 
 5. Nanosonosensitizers 
 The addition of particles to a liquid, in the appropriate size 
and amount, leads to an increase in cavitation bubbles and 
liquid temperature once ultrasound is applied. This suggests 
that the enhancement in the yield of sonochemical reaction 
by appropriate particle addition comes from an increase in 
the number of cavitation bubbles. Thus, the article of Tuziuti 
et al.  [39] clarifi es the fact that particle addition has the poten-
tial to enhance the yield of the sonochemical reactions, leading 
to an increasing interest in using nanoparticles as sonosensi-
tizers. Moreover, nanomaterials have some features that make 
them particularly suitable for SDT from a pharmacological 
point of view, i.e., their being hydrophobic, having an enor-
mous surface area that can be modifi ed with functional groups 
that have a diverse array of chemical or biochemical proper-
ties, and a subcellular and submicrometer size that allows the 
nanoparticles to penetrate deeply into tissues with ease and be 
effi ciently taken up by the cells (Figure  5 ). For example, gold 
nanoparticles are useful for SDT owing to their special optical 
properties. The low toxicity, good uptake by mammalian cells, 
and antiangiogenetic properties of gold nanoparticles make 
them highly attractive for medical applications  [40] . Again, 
as inorganic nanoparticles often interact strongly with light, 
they can be used as therapeutic agents and diagnostic tech-
niques for SDT. Indeed, research in this fi eld has been carried 
out on the use of nanoparticle titanium dioxide (TiO 2 )  [41] . It 
is well known that, upon exposure to ultraviolet (UV) light, 
TiO 2 particles can produce electrons, which lead to the forma-
tion of ROS, such as hydrogen peroxide, hydroxyl radicals, 
and superoxides. Furthermore, TiO 2 was directly activated 
under the irradiation of UV and the potent toxicity of TiO 2 
has been combined with UV irradiation for use in melanoma 
C32 cells  in vitro  [41] . Moreover, it has been shown to inhibit 
tumor growth in a mouse xenograft model. However, the use 
of nanoparticle TiO 2 still has some drawbacks, such as insuf-
fi cient selectivity and low effi ciency due to lack of cell-
specifi c accumulation of the particles in cancer cells  [41] . Xu 
et al.  [42] reported that the combination of the electroporation 
and the conjugation of TiO 2 with the monoclonal antibody 
could improve the photo-killing selectivity and effi ciency of 
photo-excited TiO 2 on cancer cells in PDT. Chihara et al.  [43] 
found that liposome-encapsulated TiO 2 might be more effec-
tive than non-coated TiO 2 in the treatment of bladder cancer, 
and these modifi ed TiO 2 might also be a more effective mate-
rial for SDT because ultrasound irradiation is an alternative 
energy source for TiO 2  [43] . The recent clinical introduction 
of HIFU, the non-invasive thermal ablation method that can 
be targeted to tissues without damaging surrounding normal 
structures, could be applied as an alternative method to locally 
irradiating tumors in combination with TiO 2  [41] . Yamaguchi 
et al.  [44] hypothesized that sonocatalytic TiO 2 might become 
a new tool in SDT for various cancers involving malignant 
glioma and developed a novel water-dispersed TiO 2 nano-
particle, modifi ed by PEG, demonstrating its photocatalytic 
antitumor effect on a glioma cell line. These nanoparticle 
compounds are approximately 50 nm in diameter and do not 
cross the blood-brain barrier (BBB) in the normal brain. On 
the contrary, the accumulation of the particles in malignant 
glioma by transvascular delivery can expected because the 
normal BBB is disturbed in the tumor site  [45] . As the long-
term side effects of inorganic nanoparticle accumulation in 
body organs are still unknown, luminescent silica nanopar-
ticles that decompose in an aqueous solution over a period 
of hours have been developed  [46] . Furthermore, Osminkina 
et al.  [47] reported an  in vitro anticancer effect of silicon 
nanocrystals used as a sonosensitizer. 
 6. Complementary approach: nanoparticles for 
photoacoustic imaging 
 Molecular imaging is a new biomedical research fi eld that 
enables the visualization, characterization, and quantifi cation 
of biological processes that take place at the cellular and sub-
cellular levels within living tissues, including imaging modal-
ities, such as that of photoacoustic and ultrasound imaging 
 [48] . Molecular imaging always involves an accumulation of 
contrast agent in the target site; therefore, it has become evi-
dent that several of the challenges facing molecular imaging 
may be overcome by use of nanostructured materials such as 
nanoparticles. However, for physical reasons, nanoparticles 
have no role in ultrasound imaging because the frequencies 
necessary to detect particles smaller than 1000 nm diameter 
exceed 30 MHz, and when these are >30 MHz, they do not 
penetrate into living tissues for more than a few millimeters. 
Furthermore, contrast media are based on air-liquid inter-
faces of high curvature (bubbles), and the creation of can-
onized bubbles is no easy feat. In ultrasound imaging, this 
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gave evidence to the principle that molecular imaging can be 
achieved using microparticles (microbubbles, with diameters 
generally larger than about 5  μ m)  [49] . Ultrasound generated 
by optical stimulation of structures within a living tissue and 
nanoparticles may have important roles in  “ photoacoustic 
imaging ” (PAI). Near-infrared optical imaging and PAI are 
both strong candidates when dealing with structures that are 
close to the surface, such as peripheral arteries and veins, 
which are of considerable interest in the screening of athero-
sclerosis  [50] . PAI, sometimes called optoacoustic or ther-
moacoustic imaging, is a promising novel imaging modality 
for the non-invasive visualization of semitransparent objects, 
including soft biological tissues and biological samples. 
When short pulses of electromagnetic radiation, such as light 
or radio waves, illuminate a semitransparent object, a sound 
wave is induced at the point of interest deep within the sam-
ple  via the thermoelastic effect  [50] . The goal of PAI is the 
recovery of the spatially varying distribution of the absorbed 
energy inside the illuminated sample from the acoustic pres-
sure measured outside the sample. As structures of different 
biological tissues reveal highly varying optical absorption 
coeffi cients, PAI makes a good distinction between malignant 
and healthy tissue. 
 Moreover, in the foreseeable future, it is expected to be 
useful in the early detection of cancer and blood-rich lesions 
 in vivo and it is also expected to provide high resolution in 
microscopy  [50] . Cancer detection using PAI with endo-
genous chromophores (e.g., hemoglobin and melanin) is an 
area of active research. One such report is on PAI that used to 
monitor melanoma tumor growth over the course of 2 weeks 
 [51] . Optical contrast was provided by a higher concentra-
tion of melanin in the tumor compared with the surrounding 
tissue. PAI can also provide information on angiogenesis or 
vascular changes  [52 – 54] . 
 PAI systems have not only been used in the imaging of 
melanin and blood vessels but also in the measurement of 
blood oxygen content by comparing the photoacoustic signal 
strength of HbO 2 and Hb obtained from spectroscopic photo-
acoustic images to study hypoxia in tumors, a negative prog-
nostic factor often linked to therapy resistance  [55, 56] . 
 PAI has also been used to detect circulating tumor cells in 
the bloodstream, with the goal of detecting metastasis with 
contrast agents targeted to circulating tumor cells  [57, 58] . 
Indeed, PAI has been shown to have the potential to identify, 
visualize, and track tumors and their associated vasculature 
with high resolution  [59] . The sensitivity of the PAI technique 
to image deeply situated tumors can be further enhanced by 
exogenous contrast agents. Near-infrared-absorbing dyes, 
such as IRDye800CW  [60] , AlexaFluor 750  [61] , and indo-
cyanine green  [62] , have been used to enhance photoacoustic 
contrast. 
 However, among the various exogenous contrast agents, 
gold nanoparticles have attracted special attention due to 
their unique optical properties from the surface plasmon reso-
nance effect, i.e., gold nanoparticles have an absorbance that 
is orders of magnitude higher than that of near-infrared dyes. 
For example, gold nanospheres, nanorods, nanoshells, nano-
cages, and nanobeacons have been used in PAI because of 
their tunable and strong longitudinal plasmon resonance in 
the near-infrared spectrum  [59] . Specifi c molecular informa-
tion regarding tumors can be obtained by attaching target-
ing moieties to exogenous agents. Gold nanoparticles with 
different optical absorption properties can be conjugated to 
cancer-specifi c biomarkers, such as growth factor receptors 
and integrins. Multiple targeted gold nanoparticles allow for 
multiplex molecular labeling of a tumor and multiwavelength 
PAI can evidence the heterogeneous accumulation and inter-
action of gold nanoparticles with cancer cells  in vivo  [59] . 
 Recently, emphasis has been placed on multimodal nano-
systems that can enhance contrast in two or more imaging 
modalities, including nanowontons consisting of a ferromag-
netic (cobalt core) core coated with gold for biocompatibil-
ity and a unique shape that enables optical absorption over a 
broad range of frequencies. The magnetic core acts as a mag-
netic resonance imaging contrast agent and the gold coating 
provides the optical absorption contrast for the PAI  [63] . The 
evolution of combined imaging strategies foresees a promi-
nent role in cancer detection and treatment for multimodal 
nanostructures. Indeed, imaging techniques also have signifi -
cant roles in cancer therapy, from precise planning and guid-
ing to the evaluation of effi cacy. PAI has shown a particular 
potential in therapies by providing a sequential monitoring of 
tumor functional properties, such as changes in the tumor vas-
culature before, during and after therapeutic procedures. Due 
to their high optical absorption properties in the near-infrared 
region, the therapeutic agents used for PDT can also act as 
photoacoustic contrast agents, e.g., PPIX for PDT  [29] and 
gold nanoparticles for photothermal therapy  [64] . 
 PAI has an enormous potential in guiding therapeutic pro-
cedures and could well provide oncologists with structural 
and functional information on tumors to facilitate person-
alized therapy by customizing the therapy dose. Moreover, 
PAI can also be of help in customizing drug delivery with 
the use of multifunctional nanoparticles. An example of such 
a nanoagent is a silver nanosystem involving a poly(lactic-
co-glycolic acid) (PLGA) polymer core and outer silver cage 
network. The outer silver cage enhances contrast in PAI, and 
the inner core of the nanosystem contains the drug doxorubi-
cin. Preliminary studies have indicated that the PLGA-based 
nanosystems have the potential to increase contrast signifi -
cantly in PAI while simultaneously delivering customized 
payloads of drug to the tumor cells  [65] . Another example 
of controlled and customized drug delivery is that of the use 
of light-triggered nanoconstructs, such as microspheres con-
taining the drug paclitaxel encapsulated in hollow gold nano-
spheres. Depending on the concentration of gold nanospheres 
in the tumor, the light dose can be adjusted to allow for the 
correct release of paclitaxel  [66] . 
 7. Summary and future directions 
 Even though early results are promising  [10, 27, 31, 44, 67, 
68] , perspectives are encouraging, and nanotechnology and 
SDT hold out the possibility of a cancer therapy, to date, 
nanosonotechnology is still in its early stage. Indeed, further 
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research, both  in vitro and  in vivo , is required before it can be 
considered a clinical therapeutic tool against cancer. However, 
it has been demonstrated that nanoparticles can improve 
sonosensitizer bioavailability  [30] and cancer targeting  [69] , 
opening new horizons in the development of a next genera-
tion of nanosonosensitizers, such as gold nanoparticles that 
carry PPIX  [68] . As PPIX acts as a classical sonosensitizer 
and the gold nanoparticles increase the cavitation rate  [70] , it 
might be feasible to suppose that a synergistic effect on tumor 
cell killing is enhanced by the capability gold nanoparticles 
to increasing the amount of PPIX in the tumor cells. Indeed, 
in the presence of gold nanoparticles, the relaxation time of 
PPIX is longer than the time required for PPIX without gold 
nanoparticles  [71] and favors an effi cient generation of sin-
glet oxygen. 
 Gold nanoparticle-PPIX conjugate has a greater potential 
than does PPIX alone as a sonosensitizer in the treatment 
of CT26 tumors by SDT. Such a fi nding can be related to a 
higher uptake of PPIX by the tumor cells through its nano-
particle carriers and the presence of gold nanoparticles as an 
enhancer of cavitation bubbles  [67] . 
 Furthermore, the new generation of PAI nanosonosensiti-
zers might improve the therapeutic tools used against cancer. 
However, despite recent progress, optically active inorganic 
nanoparticles have not yet achieved broad clinical implemen-
tation, possibly due to the fact that drug loading is typically 
limited to the nanoparticle surface and there is still some 
concern about long-term safety, prompting further neces-
sary investigation into the toxicity of inorganic nanoparticles 
 [64, 72] . Conversely, organic nanoparticles have found many 
human therapeutic applications due to their strong biocom-
patibility and drug-delivery capacity  [73] . However, as these 
organic nanoparticles generally do not intrinsically absorb 
light in the near-infrared region, they have been of limited 
use for biophotonics. This led Lovell et al.  [74] to introduce 
porphysomes, organic nanoparticles that are self-assembled 
from phospholipid-porphyrin conjugates and exhibit liposome-
like structures and loading capacity, high absorption of near-
infrared light, structure-dependent fl uorescence quenching, 
are enzymatically biodegradable and have an excellent bio-
compatibility. Porphysome are formed by supramolecular 
self-assembly, and the subunits consists of porphyrin-lipid 
conjugates generated by an acylation reaction between lyso-
phosphatidylcholine and pyropheophorbide, a chlorophyll-
derived porphyrin analogue. This hydrophobic chromophore 
was positioned in place of an alkyl side chain, maintaining 
an amphipathic structure. A concentration of 5 mol % PEG-
lipid was included in the formulation to enhance  in vivo phar-
macokinetics. Moreover, it has a stabilizing effect because 
PEG maintained their size and monodispersity for at least 
9 months  [75] . Porphysome are spherical vesicles measuring 
100 nm in diameter, with two layers of higher-density mate-
rial separated by a 2-nm gap, corresponding to two separate 
monolayers of porphyrin. They can form metal-chelating 
bilayers and are useful in a scenario where specifi c oper-
ating wavelengths are required. As porphysomes are higly 
self-quenched, energy that would normally be released to 
fl uorescence and singlet-oxygen generation is dissipated 
elsewhere  [74] . Porphysomes are intrinsically suited for 
multimodal imaging, such as photoacoustic tomography, 
and, together with other gold and magnetic nanoparticles, is 
promising approach in non-invasive detection of circulating 
cancer cells in blood vessels  [76] as well as in sentinel lymph 
nodes  [77] . In conclusion, it may be inferred that nanotech-
nology and SDT are two valuable approaches that can slow 
down the process of tumor growth, but the combination of 
 “ nanosonotechnology ” might open an innovative and more 
effective scenario in cancer therapy. 
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